Bosutinib

BNF:
8.1.5
Status:
Do Not Prescribe (DNP), Red
Decision Date:
September 2016
 

Comments

RED:

  • NICE TA401: for previously treated chronic myeloid leukaemia.  Is recommended within its marketing authorisation for treating Philadelphia-chromosome-positive chronic myeloid leukaemia.  (NHSE commissioned).  (Decision date - September 2016).

Do Not Prescribe (DNP):

  • NICE TA576: for untreated chronic myeloid leukaemia.  (Terminated appraisal).  (Decision date - May 2019).

NHS England drug.  To be used in line with NHSE commissioning intentions.  

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app